Patent intelligence · US
US 8940300
Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods
Patent details — US 8940300
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 27, 2015
- Expiration
- Jan 22, 2035
- Applicant
- ADHERON THERAPEUTICS, INC.
- Claims
- 9
- CPC classes
- A61K, A61K2039/505, A61K39/39541, A61K39/3955
Quick answer
US 8940300 (Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods) is held by ADHERON THERAPEUTICS, INC.. Status: granted. Granted Jan 27, 2015. Expires Jan 22, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ADHERON THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 9
- CPC classes
- A61K, A61K2039/505, A61K39/39541, A61K39/3955, A61K45/06, A61P
More from ADHERON THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12318376
Compositions of a polyorthoester and an aprotic solvent
granted -
US 12290520
Methods of use of emulsion formulations of aprepitant
granted -
US 12115254
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 12115255
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11878074
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11844837
Compositions of a polyorthoester and an organic acid excipient
granted -
US 11744800
Methods of use of emulsion formulations of an NK-1 receptor antagonist
granted -
US 11413350
Long-acting polymeric delivery systems
granted
Frequently asked questions
What is US patent 8940300?
US 8940300 (Humanized antibodies targeting the EC1 domain of Cadherin-11 and related compositions and methods) is held by ADHERON THERAPEUTICS, INC.. Status: granted. Granted Jan 27, 2015. Expires Jan 22, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8940300?
ADHERON THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 46 pharmaceutical patents for this assignee.
When does US 8940300 expire?
Our index shows an expiration date of Jan 22, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.